UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

Clinical cancer research, 2010-05, Vol.16 (10), p.2861-2871

2010

Volltextzugriff (PDF)

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

Cancer immunology research, 2013-10, Vol.1 (4), p.229-234

2013

Volltextzugriff (PDF)

TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer

Nature communications, 2024-07, Vol.15 (1), p.5291-13, Article 5291

2024

Volltextzugriff (PDF)

CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy

Cancer immunology research, 2014-02, Vol.2 (2), p.167-176

2014

Volltextzugriff (PDF)

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

Cancer immunology research, 2019-11, Vol.7 (11), p.1803-1812

2019

Volltextzugriff (PDF)

TAK, an HIV Tat-Associated Kinase, is a Member of the Cyclin-Dependent Family of Protein Kinases and is Induced by Activation of Peripheral Blood Lymphocytes and Differentiation of Promonocytic Cell Lines

Proceedings of the National Academy of Sciences - PNAS, 1997-11, Vol.94 (23), p.12331-12336

1997

Volltextzugriff (PDF)

NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

Clinical cancer research, 2009-03, Vol.15 (6), p.2130-2139

2009

Volltextzugriff (PDF)

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer

Cancer immunity, 2007-06, Vol.7, p.10-10

2007

Volltextzugriff (PDF)

Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy

Cancer immunity, 2008-05, Vol.8, p.9

2008

Volltextzugriff (PDF)

CTLA-4 blockade increases IFNγ-producing CD4⁺ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (39), p.14987-14992

2008

Volltextzugriff (PDF)

Anti-CTLA-4 therapy results in higher CD4⁺ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Proceedings of the National Academy of Sciences - PNAS, 2009-02, Vol.106 (8), p.2729-2734

2009

Volltextzugriff (PDF)

Antiapoptotic Function of Cdk9 (TAK/P-TEFb) in U937 Promonocytic Cells

Journal of Virology, 2001-02, Vol.75 (3), p.1220-1228

2001

Volltextzugriff (PDF)

Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide

Cancer discovery, 2012-02, Vol.2 (2), p.122-130

2012

Volltextzugriff (PDF)

Investigating genes and micro-RNAs that may predict clinical benefits of anti-CTLA-4 therapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3043-3043

2013

Volltextzugriff (PDF)

A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.285-285

2013

Volltextzugriff (PDF)

Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.505-505

2017

Volltextzugriff (PDF)

Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2520-2520

2012

Volltextzugriff (PDF)

Abstract 1265: Sustained PI3-kinase signaling is mediated by ICOS, not CD28, for anti-tumor T-cell responses elicited by anti-CTLA-4

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1265-1265

2013

Volltextzugriff (PDF)

Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5368-5368

2012

Volltextzugriff (PDF)

Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial

Clinical cancer research, 2010-05, Vol.16 (10), p.2861-2871

2010

Volltextzugriff (PDF)

CTLA-4 blockade increases IFN[gamma]-producing CD4+ICOS^sup hi^ cells to shift the ratio of effector to regulatory T cells in cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (39), p.14987

2008

Volltextzugriff (PDF)

CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (39), p.14987-14992

2008

Volltextzugriff (PDF)

CTLA-4 Blockade Increases IFNγ-Producing ${\rm CD}4^{+}{\rm ICOS}^{{\rm hi}}$ Cells to Shift the Ratio of Effector to Regulatory T Cells in Cancer Patients

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (39), p.14987-14992

2008

Volltextzugriff (PDF)

CTLA-4 blockade increases IFN gamma -producing CD4 super(+)ICOS super(hi) cells to shift the ratio of effector to regulatory T cells in cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (39), p.14987-14992

2008

Volltextzugriff (PDF)

Anti-CTLA-4 therapy results in higher CD4 super(+)ICOS super(hi) T cell frequency and IFN- gamma levels in both nonmalignant and malignant prostate tissues

Proceedings of the National Academy of Sciences - PNAS, 2009-02, Vol.106 (8), p.2729-2734

2009

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(48)
Tagungsberichte
(1)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Science & Technology
(23)
Life Sciences & Biomedicine
(20)
Immunology
(9)
Aids/hiv
(7)
Tumors
(7)
Male
(6)
Oncology
(6)
Antibodies
(5)
Antibodies, Monoclonal - Therapeutic Use
(5)
Biological And Medical Sciences
(5)
Cancer
(5)
Cd4-Positive T-Lymphocytes - Immunology
(5)
Female
(5)
Ipilimumab
(5)
Urinary Bladder Neoplasms - Immunology
(5)
Aged
(4)
Antigens
(4)
Apoptosis
(4)
Clinical Trials
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer

CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

TAK, an HIV Tat-Associated Kinase, is a Member of the Cyclin-Dependent Family of Protein Kinases and is Induced by Activation of Peripheral Blood Lymphocytes and Differentiation of Promonocytic Cell Lines

NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer

Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy

CTLA-4 blockade increases IFNγ-producing CD4⁺ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

Anti-CTLA-4 therapy results in higher CD4⁺ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Antiapoptotic Function of Cdk9 (TAK/P-TEFb) in U937 Promonocytic Cells

Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide

Investigating genes and micro-RNAs that may predict clinical benefits of anti-CTLA-4 therapy

A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy

Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma

Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy

Abstract 1265: Sustained PI3-kinase signaling is mediated by ICOS, not CD28, for anti-tumor T-cell responses elicited by anti-CTLA-4

Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma

Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial

CTLA-4 blockade increases IFN[gamma]-producing CD4+ICOS^sup hi^ cells to shift the ratio of effector to regulatory T cells in cancer patients

CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients

CTLA-4 Blockade Increases IFNγ-Producing ${\rm CD}4^{+}{\rm ICOS}^{{\rm hi}}$ Cells to Shift the Ratio of Effector to Regulatory T Cells in Cancer Patients

CTLA-4 blockade increases IFN gamma -producing CD4 super(+)ICOS super(hi) cells to shift the ratio of effector to regulatory T cells in cancer patients

Anti-CTLA-4 therapy results in higher CD4 super(+)ICOS super(hi) T cell frequency and IFN- gamma levels in both nonmalignant and malignant prostate tissues

Suchergebnisse filtern